Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.

Date publication

août 2025

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Pyne L, Rossignol P, Giles C, Junek M, Mark PB, Gallagher M, de Zoysa JR, Devereaux PJ, Walsh M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40840478

Résumé

Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain. We aimed to assess the efficacy and safety of mineralocorticoid receptor antagonists in this patient population.

Mots clés

Humans, Mineralocorticoid Receptor Antagonists, therapeutic use, Randomized Controlled Trials as Topic, Renal Dialysis, Cardiovascular Diseases, mortality, Kidney Failure, Chronic, therapy, Male, Female, Renal Insufficiency, therapy

Référence

Lancet. 2025 08 23;406(10505):811-820